Research Triangle Park
-
A One-Time Treatment for NASH? Kriya Strikes Deal for Liver Disease Gene Therapy
Gene therapy biotech Kriya Therapeutics has acquired Tramontane Therapeutics, a startup focused on metabolic diseases. Tramontane brings a gene therapy that’s a potential one-time treatment for the fatty liver disease NASH.
-
Adverse Survival Signal Leads G1 to Stop Pivotal Test in Colorectal Cancer
G1 Therapeutics said its drug met the main goal of a Phase 3 study in colorectal cancer, but the preliminary results also show measures of survival are better in the placebo arm. The company is stopping the colorectal cancer study.
-
Payer’s Place: Dawn Maroney
Dawn Maroney, President, Markets of Alignment Health and CEO of Alignment Health Plan, to discuss how they are using technology to provide better service and care to consumers.
-
For Neuro Biotech Lusaris, Depression Therapy Starts by Lifting the Tongue
Lusaris Therapeutics launched with $60 million for clinical development of a psychedelic depression drug it claims will be easier to dose and fast-acting. The company was formed and incubated by RA Capital Management, which led the startup’s Series A round of financing.
-
FDA finally signs off on Fennec Pharma drug for chemo-caused hearing loss in kids
A Fennec Pharmaceuticals drug that prevents hearing loss in children receiving cancer treatment is now approved. The regulatory decision comes more than two years later than expected, but the company now claims its drug, Pedmark, is the first and only FDA-approved therapy for reducing the risk of chemotherapy-induced hearing loss in pediatric cancer patients.
-
Artificial Intelligence, BioPharma
Creyon Bio gets some green for a new take on AI and genetic meds R&D
Creyon Bio is the latest company to launch with artificial intelligence technology for drug R&D. The startup claims its technology can provide sufficient safety and toxicity data to enable a therapy to bypass the animal research currently needed before clinical trials.
-
Bayer paying up to $4B for gene therapy pioneer AskBio
The deal, offering $2 billion up front and $2 billion in future milestone payments, includes a gene therapy manufacturing facility and a pipeline that includes treatments for Parkinson’s and congestive heart failure.
-
FDA OKs Cellex’s antibody-based test for Covid-19
The agency granted an emergency use authorization to the company for its test, which is meant to detect antibodies against SARS-CoV-2 in the blood. However, antibody testing has both advantages and disadvantages relative to the more common PCR assays.
-
New report offers good news on drug spending, opioid prescriptions
The use of coupons and manufacturer buydowns is increasing as a way to offset what would otherwise be increasing costs borne by the patients, according to Murray Aitken, senior vice president and executive director of the IQVIA Institute for Human Data Science,
-
Quintiles uses Solution Design Studio in journey to integrate digital tech with clinical trials
In June, Quintiles launched a continuous glucose monitoring service, combining consumer wearable devices and medical device CGM to record glucose readings throughout the day.
-
Applying Remote Patient Monitoring to Surgery Prep and Recovery, Oncology and Women’s Health
Join us to learn about the latest trends in remote monitoring and how to extend its benefits beyond chronic conditions to more patients – all while using fewer staff resources.
-
When CEOs talk, but don’t really say anything
CEO of surgical robotics company TransEnterix talks of interactions with FDA that rejected its 510(k) application but refuses to divulge the reason that led to the agency’s negative decision frustrating analysts and investors.
-
Bivarus raises $2M to add staff for patient-centered analytics, roll out data visualization engine
New investor Hatteras Venture Partners and existing investor Excelerate Health Ventures co-led the round.
-
Cloud Pharmaceuticals eyeing $10 million round
It also projects $5 million in revenue this year.
-
Validic inks deal with Quintiles to do remote monitoring for clinical trials
The move will help Quintiles improve the frequently costly, lengthy recruitment process for clinical trials.
-
Health IT, Daily, Patient Engagement
A closer look at TEXT ME clinical trial reveals 5 ways to improve clinical validation of apps
Among the observations: it’s not good enough to look at apps as a standalone intervention strategy.
Promoted
Payer’s Place: Dr. Anil Singh
Dr. Anil Singh shares his insights into the strategies employed by the organization to identify the most effective digital solutions for their members.
Promoted
Discover the Next-Gen Platform for Integrated Collaborative Care
Beyond EHRs and digital front doors, reducing the gaps in patient care journeys.
